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Abstract Cancer cachexia is a complex syndrome charac-
terized by inflammation, body weight loss, muscle, and
adipose tissue wasting that is responsible for the death of a
considerablepercentageofcancerpatients. Inaddition, during
cachexia muscle strength and endurance are dramatically re-
duced, limiting the ability to perform daily activities and
severelyaffectingthepatient’squalityoflife. Differentstudies
have emphasized that a single therapy may not be completely
successful in the treatment of cachexia. Beyond pharma-
cological strategies, exercise training has been suggested
as a promising countermeasure to prevent cachexia, in
order to restore both strength and endurance, depending
on the type of exercise. Unfortunately, a small number of
studies, in both clinical and experimental settings, have
been performed to date. Moreover, when considering exercise
in cancer, several factors have to be taken into consideration,
in particular those alterations that could limit the capacity to
perform exercise and consequently the resulting beneficial or
detrimental effects. This editorial is aimed at stimulating the
debate on the suitability of including exercise training in a
multi-functional approach against cachexia taking into con-
sideration both limitations and advantages.
Cachexia is a multiorganic syndrome associated with can-
cer, characterized by inflammation, body weight loss (at
least 5 %) and muscle and adipose tissue wasting [1]. The
abnormalities associated with cachexia include alterations in
carbohydrate, lipid and protein metabolism, often associated
with anorexia [1–3]. Cachexia occurs in the majority of
subjects with cancer before death, and it is responsible for
the deaths of approximately 20 % of cancer patients [4],
although the percentage may be even higher, depending on
cancer type [5]. In addition, survival of patients affected by
different types of neoplasias is clearly dependent on the
presence of weight loss [6]. Therefore, cachexia prevention
represents an important factor in the treatment of cancer
patient, affecting not only survival but also the tolerance to
anti-cancer treatment, quality of life and, ultimately, sanitary
costs. It is thus clear that there is both a medical and a social
need for the treatment of cancer cachexia. Although anorexia
represents a very important factor in the development of
cachexia, it has to be pointed out that in many cases the use
of total parenteral nutrition does not stop the loss of body
weight [7]. It seems, therefore, quite evident that metabolic
disturbances present in the host have a definitive role in the
development of cachexia [2, 7]. Among these, increased
energy inefficiency, insulin resistance, abnormal carbohy-
drate metabolism, adipose tissue dissolution, hyperlipidemia,
and muscle wasting are the most relevant. Because metabolic
alterations often appear soon after the onset of tumor growth,
the scope of appropriate treatment, although not aimed at
achieving immediate eradication of the tumor mass, could
influence the course of the patient’s clinical state or, at least,
prevent the steady erosion of dignity that the patient may feel
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DOI 10.1007/s13539-012-0067-5in association with the syndrome. This would no doubt con-
tribute to improving the patient’s quality of life and, possibly,
prolong survival.
Different studies have emphasized that a single therapy
may not be completely successful in the treatment of
cachexia. From this point of view, treatments involving
different combinations are more likely to be successful
[8]. A very interesting phase II study, involving the
administration of antioxidants, pharmaconutritional support,
progestagen, and anti-cyclooxygenase-2 drugs, showed effi-
cacy and safety in the treatment of patients with advanced
cancer of different sites suffering cachexia [9]. Based on the
results of the Phase II study a randomized Phase III study
started in 2005 with the aim to include more than 300
cachectic cancer patients and it is still in progress. These
data clearly reinforce the use of these multitargeted therapies
in the treatment of the cachexia–anorexia syndrome in
cancer. Beyond pharmacological strategies, exercise train-
ing has been suggested as a promising countermeasure to
prevent cachexia [10]. Unfortunately, a small number of
studies, in both clinical and experimental settings, have been
performed in order to define the effectiveness of exercise
againstcachexia. The rationale for the useof exercise is quite
simple; ithasbeendemonstrated thatduringcachexiamuscle
strength and endurance are dramatically reduced [11–14].
Such alterations severely limit the ability to perform daily
activities and consequently compromise the patient’s quality
of life. Exercise training, on the contrary, is able to increase
both strength and endurance in healthy conditions, depend-
ing on the type of exercise. Moreover, it has been proven to
act as an excellent anabolic drive for skeletal muscle in
combination with anabolic steroid or other muscle anabolic
drugs [15].
1 Limitations to exercise in cancer
When considering exercise in cancer, several factors have to
be taken into consideration, in particular those alterations
that could limit the capacity to perform exercise and
consequently the resulting beneficial or detrimental
effects. Actually, many cancer patients suffer from chronic
Table 1 Body and muscle weight in control (n06), colon26-bearing (C26, n08), exercised (n06, 14 m/min 45 min, 5 days/week on a treadmill) and
C26 exercised (n08)
Controls C26 Exercise C26 exercise
Initial b.w. (g) 21.06±1.02 20.88±0.79 20.82±1.15 20.76±0.60
Final b.w. (g) 23.94±1.29 20.06±1.37 23.84±1.34 17.42±1.73
Δ b.w. (g) +2.88±0.57 −0.82±1.23** +3.02±0.63 −3.34±1.60***
, ****
GSN mass (mg/100 g i.b.w.) 572±25 471±49** 581±26 408±54***
, ****
Hematocrit (%) 51±4 42±7 * 54±2 44±6 *
The hematocrit was measured collecting the blood by means of cardiac puncture from anesthesized mice before sacrifice. Data are expressed as
mean±standard deviation
*p<0.05 vs. control; **p<0.01 vs. control; ***p<0.001 vs. control; ****p<0.05 vs. C26
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Fig. 1 Diagram depicting the
effects of endurance exercise
in cancer cachexia
74 J Cachexia Sarcopenia Muscle (2012) 3:73–76fatigue, either from the disease itself or its treatment, the latter
being a confounding factor that limits exercise practice. As a
matter of fact, recent data from our laboratory suggest that
exercisemaybenotadvisablewhenanemiaispresent.Indeed,
as can be seen in Table 1, when tumor-bearing mice suffering
from a significant decrease in hematocrit are exercised (mild
endurance training), their condition worsens. It was reported
that anemia is a frequent feature of patients with cancer
cachexia, contributing to weight loss, reduced exercise
capacity, and altered energy homeostasis [16]. The inci-
dence of anemia varies with tumor type, stage and
patient’s age: up to one-third of cancer patients are anemic
at diagnosis [17] and chemotherapy can even increase this
number. Cancer-associated anemia can thus be considered
a negative prognostic factor for survival, regardless of
tumor type [18]. The mechanisms by which anemia may
contribute to the onset and progression of cachexia still
needtobeelucidated,however,inthedesignofatherapeutical
approach against cachexia that include exercise training, it is
mandatory to correct anemia first, in order to rescue the
tolerance to the exercise.
Although relevant, anemia is not the unique factor limiting
exercise capacity in cancer, since recent data have reported
functional and structural cardiac alterations in tumor-bearing
mice [19]. Anemia and cardiac dysfunctions likely act syner-
gistically lowering the threshold of exercise intensity that
discriminate between the beneficial adaptations induced by
mild exercise and the deleterious effects of strenuous exercise
(Fig. 1). Thus, the exercise dose is a crucial point to be
carefully evaluated on a single patient basis. Nonetheless,
the mode of exercise to be performed in a cancer patient
population is very important, although a consensus is still
lacking. Considering the maintenance of muscle mass as the
primary goalto be achieved incachexia, resistance rather than
endurance exercise appears to be preferred. Indeed, while the
formerexertsananabolicaction,thelatterstimulatesoxidative
metabolic adaptations with little changes in muscle mass.
However, the resistance induced anabolism does not neces-
sarilyimplyananticataboliceffect.Indeed,resistanceexercise
in healthy conditions stimulates the Akt/mTOR signaling
pathway [20], this being reported to be unaffected or even
hyperactivated in tumor-bearing animals [21], suggesting the
uselessness of Akt stimulation to prevent muscle wasting in
cancer cachexia. On the contrary, mild endurance exercise
might counteract the reduction of oxidative capacity found
in experimental cachexia [22]. The stimulation of oxidative
metabolism could directly prevent the hyperlipidemia, and
consequently ameliorate the insulin resistance. Finally, en-
durance exercise induces physiological adaptations resulting
in the attenuation of the inflammatory response [23]( F i g .1).
As a result, endurance exercise has been the exercise mode of
choice in the majority of atrophy countermeasure studies
performed to date. A recent meta-analysis [24]r e p o r t e d
differential effects exerted by exercise, depending on the
pathology considered and the type of exercise performed: a
global positive effect of exercise was observed when all the
pathologies considered were pooled together. It is interesting
to speculate that lower than previously recognized volumes of
exercise are quite likely to have a measurable and positive
impact in neutralizing muscle loss if practiced diligently and
started at early stages of the disease, even in clinical cancer
populations. Finally, the relevance of the nutritional state of
the patients should be taken into account. In this regard, the
potential benefits of exercise can be completely abrogated if
the organism does not have a good nutrient availability that
wouldallowtheeffectivecounteractionofthewastingpattern.
Thus, the management of cancer cachexia will probably be
improved by a multi-functional approach. In this regard, the
effectsofspecificanabolic/anticatabolicdrugsassociatedwith
adequatenutritional support could bepotentiated byincreased
muscle use with moderate-to-high endurance.
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